ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 148 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2020. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,409,068 | +7.8% | 184,433 | +0.5% | 0.02% | 0.0% |
| Q3 2022 | $1,307,000 | -31.1% | 183,531 | -21.8% | 0.02% | -31.8% |
| Q2 2022 | $1,898,000 | -77.1% | 234,645 | -60.7% | 0.02% | -70.7% |
| Q1 2022 | $8,285,000 | +53.5% | 596,873 | +210.4% | 0.08% | +74.4% |
| Q4 2021 | $5,396,000 | +142.1% | 192,312 | +193.2% | 0.04% | +138.9% |
| Q3 2021 | $2,229,000 | -47.0% | 65,590 | -36.2% | 0.02% | -41.9% |
| Q2 2021 | $4,204,000 | -55.9% | 102,886 | -56.5% | 0.03% | -56.9% |
| Q1 2021 | $9,525,000 | -76.9% | 236,587 | -66.1% | 0.07% | -76.4% |
| Q4 2020 | $41,211,000 | +3.8% | 696,958 | -14.7% | 0.30% | -12.1% |
| Q3 2020 | $39,715,000 | +8.7% | 816,667 | +8.1% | 0.35% | +7.4% |
| Q2 2020 | $36,549,000 | +39.0% | 755,462 | -20.2% | 0.32% | +9.5% |
| Q1 2020 | $26,300,000 | +167.7% | 946,710 | +188.3% | 0.30% | +304.1% |
| Q4 2019 | $9,824,000 | – | 328,357 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |